FDA Brief

Warning letters Biologics

FDA warning letter to

Invitrx Therapeutics, Inc.

Issued Nov 9, 2022Posted Nov 22, 2022Division of Biological Products Operations II

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). We haven't summarized this letter yet. Read it on fda.gov.